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Introduction
The continuous inflammation in livers of patients with chronic hepatitis C virus (HCV) infection may cause hepatic fibrogenesis. Progression of this process may eventually lead to cirrhosis, at which stage patients have an unfavorable prognosis due to the elevated risk of hepatocellular carcinoma (HCC) and liver failure.(1) In one of the largest studies on the fibrosis progression rate, dating back to 1997, it was estimated that 33% of patients with chronic HCV infection develop cirrhosis within 20 years.(2) However, the number of patients who develop cirrhosis could be higher over a longer period of time as fibrosis development may not be linear. In fact, as the population with chronic hepatitis C is aging, it is expected that the incidence of HCV-related cirrhosis will increase during the upcoming years. (3) The treatment of chronic HCV infection improved enormously during the last two decades. Even in case of advanced hepatic fibrosis, sustained virological response (SVR) rates over 90% can be achieved with combination regimens of direct-acting antiviral agents. (4) (5) (6) (7) (8) Several studies showed that hepatic fibrosis can regress once HCV is eradicated as causative agent of liver injury, also among patients with advanced hepatic fibrosis. (9) (10) (11) (12) (13) (14) (15) (16) However, these studies are limited by a short follow-up duration or low number of patients with cirrhosis. Also, there is significant sampling error with respect to percutaneous liver biopsy, which remains an invasive procedure with potentially severe complications so that repeated assessments of liver histology are often not feasible. (16) (17) (18) The longitudinal pattern of hepatic fibrosis regression is thus difficult to study.
The platelet count is strongly related to the degree of hepatic histopathological abnormalities and portal pressure, especially among those patients with bridging fibrosis or cirrhosis. (19) (20) (21) (22) (23) (24) (25) (26) Indeed, lower platelets have been repeatedly associated with a higher risk for cirrhosis-related morbidity and mortality, which supports that the platelet count is representative of the stage of liver disease.(1, 27-29) Importantly, the change in platelets correlated with the change in hepatic fibrosis following antiviral therapy among patients with chronic HCV infection, including those who attained SVR.(30, 31) Changes in platelets thus represent a non-invasive alternative to assess the evolution of the stage of liver disease and portal pressure. Because splenic sequestration of blood cells as a direct result of elevated portal pressure causes the spleen to increase in size, splenomegaly is also considered a non-invasive marker of the degree of portal hypertension or presence of esophageal varices. (22) (23) (24) The aim of our study was to assess the change in platelet counts following SVR in a large cohort of consecutively interferon-treated patients with chronic HCV infection and biopsy-proven bridging fibrosis or cirrhosis.
Patients and Methods
All consecutive patients with chronic HCV infection and bridging fibrosis or cirrhosis (Ishak fibrosis score 4-6) who initiated interferon-based antiviral therapy between 1990 and 2003 were included from 5 large hepatogy units in Europe and Canada. The design of this retrospective cohort study have been described in detail previously.(29) For the current study, the patients were assessed from the last received interferon-based treatment course onwards. Hereby it was prevented that interferon-induced bone marrow suppression influenced the platelet counts during follow-up as a result of retreatment. Excluded were patients with a human immunodeficiency virus or hepatitis B virus co-infection, patients who had developed HCC or liver failure prior to start of follow-up or prior to the first available platelet count measurement during follow-up, and patients who received long-term low-dose pegylated interferon maintenance therapy. Patients without follow-up beyond January 1st 2010 were invited for a single visit to the outpatient clinic.
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice. According to the standards of the local ethics committees, written informed consent was obtained from patients visiting the outpatient clinics.
This article is protected by copyright. All rights reserved.
Outcome measures
Pre-treatment markers of liver disease severity closest to the start of therapy were included, as long as these were available within six months before the start of antiviral therapy. All available platelet count measurements were registered from 24 weeks after cessation of interferon-based antiviral therapy. A platelet count <150 x10 All statistical tests were two-sided, and a p-value <0.05 was considered to be statistically significant. SPSS version 17.0.2 (SPSS Inc., Chicago, IL, USA) and SAS 9.2 PROC GENMOD (SAS institute, Cary, NC) were used for all statistical analyses.
Results

Study population
Between 1990 and 2003, 546 patients with chronic HCV infection and histological proof of advanced hepatic fibrosis received interferon-based antiviral therapy. Eight patients who were lost-to-follow-up and 8 patients who developed HCC or liver failure before 24 weeks after their initial treatment course were excluded. Of the remaining 530 patients, 125(24%) attained SVR and 405(76%) did not. During follow-up 204 patients without SVR were retreated at least once, which resulted in SVR for another 67 patients. Among retreated patients, 7 experienced a cirrhosis-related complication before 24 weeks following their last treatment course, 14 received long-term low dose pegylated interferon maintenance therapy, and 45 had no available platelet count measurement during follow-up.
These patients were excluded as well, so that the total study cohort consisted of 464 patients; 187 with SVR and 277 without SVR (Figure 1) . Table 1 summarizes the baseline characteristics according to the virological response to the last antiviral treatment course.
Platelet count in relation to hepatic fibrosis
At baseline, platelet counts were associated with histological stage of fibrosis: the median platelet count was 186 x10 Linear regression analyses were performed to assess which factors were associated with improvement of platelets following SVR ( Table 4 ). Higher body mass index (BMI) was negatively associated with the change in the platelet count (β=-1.59, standard error 0.78, p=0.043). These analyses were corrected for the baseline platelet count and the time from SVR to the last platelet count measurement.
Repeated measurement analyses showed a gradual and almost linear increase in platelets beyond the moment of SVR, while the platelet counts further declined among those patients who did not attain SVR (p<0.001; for the change within each response group as well as for the comparison between both response groups) (Figure 2 ). This article is protected by copyright. All rights reserved. 
Discussion
With this study we showed that the platelet counts improved following eradication of chronic HCV infection among patients with bridging fibrosis or cirrhosis. With a repeated measurement analysis including over 3000 platelet count evaluations, a rather linear increase in platelets was observed from the moment of SVR onwards. In contrast, patients who did not attain SVR showed a further decline. The increase in platelets continued for many years after SVR, suggesting that the histopathological abnormalities and portal pressure gradually improve among chronic HCV-infected patients with advanced liver disease who were successfully treated. This was further substantiated by the reduction in spleen size among the patients who had attained SVR. fibrosis.(28) In contrast to both above-described studies, a control group without SVR was included. As compared to pre-treatment levels, the mean platelet count was already significantly increased at the time SVR was attained (24 weeks after cessation of therapy).
An additional post-hoc assessment among the patients with SVR after approximately 5 years of follow-up indicated that the platelet counts further increased with time. In line with our findings, the platelet counts declined among patients without SVR.
With repeated measurement analyses including all platelet count assessments during follow-up, we have showed the evolution of platelets according to the virological response following antiviral therapy among patients with bridging fibrosis or cirrhosis in more detail.
Pre-treatment platelet counts were not included in these analyses as we started the followup at the time of SVR. This is important, because other mechanisms than splenic sequestration as a result of elevated portal pressure may reduce the platelet counts among This article is protected by copyright. All rights reserved. and reversal of splenomegaly is likely to remain a predominant reason for the increase in platelets once HCV is eradicated as cause of liver injury. Indeed, the change in platelets and change in spleen size were correlated in our study, which has not been shown by any of the previous studies. A limitation of the current study, however, is that data on baseline spleen size were available in only a limited number of the included patients, also because we restricted the baseline period to 6 months prior to the start of antiviral therapy.
Another interesting result of our study was that higher BMI was negatively associated with the increase in platelet counts among the patients with SVR. Currently, risk factors for disease progression following viral eradication remain largely unknown. Our finding might be explained by the presence of hepatic steatosis and inflammation among patients with high BMI. (41, 42) Although data on the presence of steatosis is lacking in our cohort, its association with higher BMI is well known. In conclusion, the platelet counts gradually increased and the spleen size decreased following achievement of SVR among chronic HCV-infected patients with bridging fibrosis or cirrhosis. This suggests that successful antiviral therapy leads to a reduction in portal pressure, probably due to regression of the histopathological abnormalities which have resulted from long-term liver injury due to chronic HCV infection. b The β indicates that for each unit increase of the predictor variable, the change in platelets will increase (in case of a positive β) or decrease (in case of a negative β) by β units. So, when specified to our multivariate analysis above, for every 1 kg/m 2 increase in BMI at baseline, the change in platelets will be 1.59 x10 9 /L lower. Twenty-four weeks after cessation of antiviral therapy was considered as time 0. The statistical significance refers to both the change within the group with SVR, the change within the group without SVR as well as the difference between both virological response groups.
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